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The continuous growth of advanced malignancies almost universally correlates with the reactivation of telomerase. While
there is still a great deal of basic and applied research to be done, telomerase remains a very attractive novel target for cancer
therapeutics. In this review, we will discuss the challenges and the pros and cons of the most promising antitelomerase
approaches currently being investigated.
Introduction:Telomeres, telomerase, and cancer
The ends of linear eukaryotic chromosomes contain specialized
structures called telomeres (reviewed in McEachern et al.,
2000; Collins, 2000). Human telomeres consist of tandem
arrays of the hexameric sequence TTAGGG, with overall telom-
ere sizes ranging from about 15–20 kbp at birth to sometimes
less than 5 kbp in chronic disease states (Aisner et al., 2002;
Forsyth et al., 2002; Collins, 2000; Kakuo et al., 1999;
Brummendorf et al., 2000, 2001; Boultwood et al., 1997). The
telomeric repeats help maintain chromosomal integrity and pro-
vide a buffer of expendable DNA (Blackburn, 2000; Fajkus et al.,
2002). The ends of telomeres are protected and regulated by
telomere binding proteins and form a t loop structure (Griffith et
al., 1999). This packaging is thought to mask telomeres from
being recognized as broken or damaged DNA (Van Steensel et
al., 1998; Smogorzewska et al., 2000; de Lange, 2002). The
inability of DNA polymerase to replicate the end of the chromo-
some during lagging strand synthesis (“end replication prob-
lem”), coupled with various possible processing events, results
in the loss of telomeric repeats each time a cell divides. Cells that
lack a compensatory mechanism to counteract this gradual loss
exhibit progressive telomere shortening. This eventually results
in a growth arrest (called replicative senescence) that is thought
to occur when one or more critically short telomeres trigger a
p53 (and perhaps RB) -regulated DNA damage response (Sherr
and McCormick, 2002; Smogorzewska and de Lange, 2002).
Human cells can temporarily bypass this growth arrest when RB
and p53 are disabled (Wright et al., 1989; Shay et al., 1991a,
1991b; Counter et al., 1992), but ultimately so many telomeres
become critically shortened that multiple chromosome end
fusions occur, resulting in loss of cell viability (“crisis”).
Telomeres provide a barrier to cancer progression by pre-
venting immortalization. Replicative senescence is postulated
to be a tumor-protective mechanism in vivo, where the number
of cell divisions required for the accumulation of multiple muta-
tions would erode existing telomeres as tumorigenesis pro-
gressed, eventually driving premalignant cells into senescence
(Wright and Shay, 2000). However, persuasive evidence that
this occurs in vivo remains elusive (Stewart and Weinberg,
2002). The ability to bypass replicative senescence by circum-
venting telomere-based growth limitations is thought to be one
critical rate-limiting step in the evolution of most malignancies
(Harley, 1991; Shay et al., 1991b). Clinically significant tumors
must have a mechanism for telomere maintenance to have the
unlimited proliferative capacity that appears to be required for
most advanced cancers. The almost universal path to overcom-
ing the telomere mitotic clock is the reactivation or upregulation
of telomerase (Kim et al., 1994; Shay and Bacchetti, 1997).
Telomerase is a cellular ribonucleoprotein enzyme responsible
for adding TTAGGG repeats onto the 3′ ends of chromosomes
(Greider and Blackburn, 1985; Morin, 1989; Collins and Mitchell,
2002; Lingner and Cech, 1998; Nugent and Lundblad, 1998). It
has two major components: the enzymatic reverse transcriptase
catalytic subunit hTERT (Nakamura et al., 1997) and the integral
RNA component (hTR or hTERC) that provides an 11 bp tem-
plate encoding the telomeric repeats to be added to the chromo-
some (Feng et al., 1995). The technically correct nomenclature
for the RNA component, hTERC, is easily confused when spo-
ken with hTERT, the catalytic protein component, so most scien-
tists have adopted the use of hTR to designate the functional or
template RNA component. Direct evidence linking telomerase
to replicative senescence was demonstrated (Bodnar et al.,
1998) by producing telomerase activity in telomerase-negative
cells following the introduction of only the hTERT component.
This resulted in telomere length stabilization and the direct
immortalization of cells without oncogenic transformation
(Morales et al., 1999; Harley, 2002) as long as cells are cultured
in adequate conditions (Ramirez et al., 2001).
Concerns about telomeres and telomerase as 
anticancer targets
There are several potential concerns that have been raised
about telomerase as an anticancer target. First, with many (but
not all) telomerase therapeutic approaches, one expects there
will be a lag phase between the time telomerase is inhibited and
the time telomeres of the cancer cells will have shortened suffi-
ciently to produce detrimental effects on cellular proliferation. If
this is correct, it would suggest that telomerase inhibitors might
be most effective in combinations with other conventional or
experimental cancer treatments (Figure 1) or in a setting of min-
imal residual disease (White et al., 2001). It is possible that in
primary human tumors there will be some very short telomeres
in most cells and that the lag phase before telomerase inhibitors
produce proliferative deficiencies in vivo may be more rapid
than that observed in tumor cell line preclinical models.
Second, while telomerase is not detected in most normal
tissues (Wright et al., 1996; Forsyth et al., 2002), inhibitors of
telomerase would potentially have detrimental effects on those
human cells that do express telomerase, such as hematopoetic
progenitor cells, germline cells, and other cells of the renewal
tissues such as the epidermis and intestinal crypts (Forsyth et
al., 2002). Although so-called transient amplifying cells divide
rapidly, the deeper stem cells from which they derive only rarely
enter the proliferative compartment (Mahmud et al., 2001).
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During the time that these stem cells are quiescent, telomerase
activity is negligible (Forsyth et al., 2002). Telomerase inhibitor
effects on stem cells may thus be minor because these telomer-
ase-competent cells only proliferate intermittently and typically
have much longer telomeres than cancer cells. In addition,
although telomerase-specific inhibitors would shorten the
telomeres in the proliferating transient amplifying stem cells, it
would not cause their immediate death; thus, typical therapeutic
side effects such as hair loss or nausea are unlikely to be major
immediate side effects of antitelomerase cancer therapy.
A third issue that has been raised about telomerase
inhibitors is that alternative mechanisms for telomere mainte-
nance have been reported in other organisms, in experimentally
derived human immortalized cell lines, and in some rare human
cancers (Lundblad, 2002; Lundblad and Blackburn, 1993; Bryan
et al., 1995, 1997; Bryan and Reddel, 1997; Henson et al.,
2002). Telomerase inhibitors might thus result in the emergence
of drug-resistant telomerase-independent cancer cells. While
this is certainly a possibility, there have been no published
reports of telomerase-positive human tumor cells being experi-
mentally converted to a telomerase-independent pathway using
telomerase inhibitors. However, the lack of ALT activation in the
setting of telomerase inhibition in cell culture could relate to the
inability of cell culture to fully recapitulate what happens in vivo.
In addition, some people believe that advanced human malig-
nancies may contain rare telomerase-independent variants.With
the long-term use of telomerase-specific inhibitors, these cells
may have a selective growth advantage.
A final concern is that telomerase inhibitors could lead to
increased genomic instability in surviving cells (Hackett and
Greider, 2002; Harrington and Robinson, 2002), leading to
more advanced or aggressive tumors. While there is some
experimental animal model evidence in support of this, espe-
cially in p53-deficient tumors (Chin et al., 1999; Gonzalez-
Suarez et al., 2001), most of the experiments treating human
cancer cell lines with telomerase inhibitors and experimental
models producing progressively shortened telomeres indicate
that these approaches generally lead to a less tumorigenic phe-
notype even, in some instances, in the absence of normal p53
function (Herbert et al., 1999; Zhang et al., 1999; Kim et al.,
2001; Boklan et al., 2002; Gonzalez-Suarez et al., 2000;
Greenberg et al., 1999; de Lange and Jacks, 1999; Franco et
al., 2002; Hahn et al., 1999; Goytisolo and Blasco, 2002).
Telomerase is unusual among cancer molecular targets
because a large body of outstanding basic science in telomere
biology has preceded development of effective lead com-
pounds, allowing potential problems to be anticipated before
evidence of efficacy in model systems is in hand, exactly the
opposite of the situation faced during most drug development.
Even though telomerase does not cause cancer and its role in
cancer is most probably permissive, cancer therapy directed at
telomerase has advanced in some instances to clinical trials to
validate safety and specificity (Vonderheide, 2002). While there
are many potential ways to interfere with normal telomerase
function, only a few of the most promising approaches in human
preclinical and clinical trials will be described in this review. For
information on mouse models of telomere function and the con-
nection between chromosomes, crisis, and cancer, the reader is
referred to a recent review (Maser and DePinho, 2002). Other
areas of telomerase inhibition (such as downregulating the hTR
and hTERT genes at the promoter level, the use of a dominant-
negative hTERT gene delivery [Hahn et al., 1999; Zhang et al.,
1999], inhibition of telomerase assembly [e.g., interfering with
p23 hsp 90 (Holt et al., 1999)], telomerase-specific phosphory-
lation inhibitors, blocking telomerase accessibility [G-
quadraplex stabilizers (Riou et al., 2002; Gowan et al., 2002;
Sun et al., 1997; Read et al., 1999)], hammerhead ribozymes
directed against hTR [Yokoyama et al., 1998], mutant template
RNA gene therapy [Kim et al., 2001], and reverse transcriptase
inhibitor approaches [Murakami et al., 1998; Strahl and
Blackburn, 1996; Gomez et al., 1998]) will not be covered and
the reader is referred to the original reports or other recent
reviews (Pathak et al., 2002; Hodes, 2001; Folini et al., 2000;
Kelland, 2001; Helder et al., 2002; Granger et al., 2002;
McKenzie et al., 1999; Neidle and Parkinson, 2002). In this
review, we will consider four areas: a gene therapy approach
that uses the proximal hTERT promoter to make a general can-
cer-specific oncolytic virus; a telomerase-specific immunothera-
py; the use of telomerase template antagonists; and the poten-
tial role of telomerase inhibitors as chemopreventive agents.
Cancer therapy directed at frequently occurring molecular alter-
ations in cancer (Hanahan and Weinberg, 2000) are starting to
show initial successes in clinical trials (Shawyer et al., 2002).
We anticipate that after a new wave of target-specific drugs
(including those that inhibit telomerase) are developed in early-
phase clinical trials, that combination of treatments (Figure 1)
will lead to prolonged periods of cancer remission and overall
better cancer patient management.
Telomerase-specific oncolytic virus
The use of tissue- or cell-specific promoters for targeting cancer
cells, while appealing, has some limitations, such as lack of
Figure 1. Theoretical approach to managing the care of cancer patients
with combinations of conventional and experimental therapies, including
telomerase inhibitors
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expression in diverse tumor types and toxic effects on normal
cells expressing the promoter. The hTERT proximal promoter
(from −1 to about −200 to −400) can be used to produce a more
universal gene therapy system, since almost all advanced
human cancer cells express telomerase and most normal cells
do not. Because the hTERT gene is regulated at the transcrip-
tion level, only tumor cells expressing telomerase activity would
activate the promoter. The approaches using “suicide gene
strategies” described so far appear promising and include gene
transfer via direct intratumor injections of plasmids or adenoviral
vectors containing the human telomerase promoter upstream
from proapoptotic genes such as the FADD gene (Koga et al.,
2001), Caspase 6 and 8 genes (Komata et al., 2001; Koga et al.,
2000), and the Bax gene (Gu et al., 2001, 2002). The use of
replication-deficient adenoviral vectors containing the hTERT
promoter are limited as a cancer therapy, since most tumor cells
will not be transduced and thus only a subset of cancer cells will
be eliminated. However, there is recent progress using the telo-
merase hTERT promoter (hTERTp) to drive a Tumor-specific
Replication competent ADdenoviral (hTERTp-TRAD) gene
therapy approach. In this approach (Figure 2), an introduced
adenoviral vector could infect both normal and tumor cells, but
the virus would only replicate in those cells that have robust
telomerase activity. Thus, the virus would replicate and eventu-
ally lyse the telomerase-expressing tumor cells and then spread
to adjacent cells over the few weeks that adenovirus is active.
There are limited normal stem-like cells that express telomer-
ase in the brain (Komata et al., 2001), and thus hTERTp-TRAD
therapy for gliomas may have few serious side effects. Immune
cells that express telomerase are not easily infected by aden-
ovirus (Gu et al., 2001; Wantanabe et al., 1996), so hematopoi-
etic cells are unlikely to be affected. Systemic hTERTp-TRAD
might be expected to have some immediate side effects on tran-
sient amplifying stem cells such as proliferating spermatocytes
in the testes, cells in the crypts of the intestine, and a subset of
cells in the basal and suprabasal layer of the epidermis (Holt
and Shay, 1999; White et al., 2001; Forsyth et al., 2002).
However, we do not expect this to be any more detrimental than
conventional cytotoxic drugs that affect all proliferating cells. In
initial experiments, the use of intratumoral hTERTp-TRAD injec-
tions may limit the ability of the adenoviral vectors to go to dis-
tant sites, and this approach could be useful for short-term
immediate tumor burden reduction. Surprisingly, in studies com-
paring a CMV-LacZ to hTERT-lacZ adenoviral vector by direct
injections into the liver and spleen of mice (tissues that are telo-
merase-positive in mice), there was essentially no β-galactosi-
dase activity with the hTERT vector but high levels with the con-
stitutive CMV promoter (Gu et al., 2001). Although this may be
due to the human TERT promoter not working well in murine
cells, it may be that normal cells in most organs do not express
telomerase at sufficiently high levels to produce functional lev-
els of downstream effector genes.
In another approach, the transcriptional regulatory
sequences from the hTERT or hTR genes were used to regu-
late the expression of the bacterial nitroreductase enzyme in
combination with a prodrug, CB1954 (Plumb et al., 2001). This
approach sensitized the cancer cells so that the prodrug very
efficiently killed the cancer cells. This approach was apparently
Figure 2. Telomerase promoter-dependent adenoviral therapy
The systemic use of the hTERT proximal promoter in a replication-competent adenoviral should have minimal effects on normal cells that do not express
telomerase activity. Cancer cells expressing telomerase activity transcriptionally activate the hTERT promoter, permitting adenoviral replication, lysis, and
spread to adjacent cells.
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much more effective compared to toxins/apoptotic genes or the
thymidine kinase/gancyclovir combination (Abdul-Ghani et al.,
2000; Majumdar et al., 2001).
hTERT immunotherapy
Tumor-associated antigens have been shown to mediate specif-
ic anticancer T lymphocyte responses resulting in tumor regres-
sion (reviewed in Vonderheide, 2002). Most previous research
has focused on tumor-associated antigens that were restricted
to only a few tumor types. The catalytic protein component of
telomerase (hTERT) qualifies as an attractive candidate as a
nearly universal tumor-associated antigen. hTERT protein is
naturally processed and hTERT peptides are presented as epi-
topes by MHC, eliciting CTL responses and protective immunity
against tumors (Nair et al., 2000; Vonderheide et al., 2001;
Minev et al., 2000). These early in vitro studies on the immuno-
genicity of hTERT peptides provide a good rationale for using
this approach for telomerase inhibition.The advantage, as in the
hTERTp-TRAD approach, is that there would be no lag period
required for telomere shortening prior to observation of cell
growth arrest and death. The major disadvantage would be that
normal cells expressing high levels of telomerase might also be
affected. However, while investigators were able to elicit a spe-
cific CTL killing of tumor cells of prostate, lung, breast, colon,
and melanoma, they did not observe a CTL effect on telomer-
ase-positive CD34+ hematopoetic cells, suggesting that hTERT
is a poor autoantigen in stem cells (Vonderheide et al., 2001).
This may be due to the relatively low level of telomerase expres-
sion in these cells as compared with tumor cells and the fact
that they do not continuously express telomerase. In ongoing
phase I clinical trials to establish safety of the approach, there
was measurable immune reactivity without any high-grade toxic
side effects (Vonderheide, 2002). While vaccinations in patients
with high-grade tumors are unlikely to be clinically effective, pre-
ventative immunotherapy could be a viable option (if there are
minimal toxicities) in patients with minimal residual disease or in
patients with a high risk for cancer development.
Targeting the RNA component of telomerase (telomerase
template antagonists)
Oligonucleotide strategies for cancer therapy directed against a
variety of molecular targets are currently in late-stage clinical tri-
als. The initial results are encouraging and indicate that the
oligonucleotides delivered systemically can enter human tumors
Figure 3. Telomerase inhibitors and conventional therapies
A telomerase inhibitor used as a single agent will progressively reduce telomere length, but there is an expected time delay until cell death. Conventional
cytoxic therapies will initially reduce tumor burden but not affect telomere length. Combinations of conventional therapies with telomerase inhibitors would
be predicted to both reduce tumor burden and shorten telomeres, potentially preventing or delaying tumor recurrences.
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in patients, find their targets, and in some instances result in
improved survival (Corey, 2000, 2002). Oligonucleotides com-
plementary to the template region of the RNA component of
telomerase (hTR) offer certain advantages as well as disadvan-
tages as a cancer therapeutic. The major disadvantage is that,
compared to telomerase promoter oncolytic viruses or the
hTERT immunotherapy, inhibiting telomerase will take time
before telomere shortening affects tumor cell survival. However,
telomerase is an intriguing target since the template region of
hTR must be exposed in order to add new telomeric repeats
onto the chromosomes, making it an accessible target for
oligonucleotides. Rather than acting by “antisense” mecha-
nisms to degrade mRNA or inhibit translation, oligonucleotides
targeting the hTR template region function as classical enzy-
matic inhibitors of telomerase activity.With typical mRNA target-
ing, as much as 90% or more inhibition may be necessary to
observe an effect, while hTR inhibitors may be effective at much
lower efficiencies.
Several classes of oligonucleotides (such a phosphodiester
DNA, phosphoramidates, peptide nucleic acids, locked nucleic
acids, 2′ O-methyl-RNA, and 2′-O-methoxyethyl RNA) targeting
telomerase have been reported (Norton et al., 1996; Pitts and
Corey, 1998; Corey, 2000, 2002; Herbert et al., 2002; Hamilton
et al., 1999; Gryaznov et al., 2001; Elayadi and Corey, 2001).
Almost all these chemistries can effectively inhibit telomerase in
intact cells. Importantly, most of these chemistries work at phar-
macological concentrations. Replacing some of the phosphodi-
ester bonds with phosphorothioate linkages results in greater
resistance to nucleases but unfortunately leads to loss of speci-
ficity (Matthes and Lehmann, 1999). In some experiments, telo-
merase template antagonists administered to intact cancer cells
have been shown to reduce telomerase activity, lead to progres-
sive shortening of telomeres, and cause cell proliferation to
decrease and apoptosis to increase in a time period proportion-
al to initial telomere length (Herbert et al., 1999). Importantly,
chemically related molecules that did not inhibit telomerase did
not cause decreased cell proliferation or telomere shortening.
When the telomerase template antagonist was removed
from the cells in culture, the surviving cells regained baseline
telomerase activity and their telomeres grew back to their origi-
nal lengths, supporting the assumption that the mechanism of
action was through a competitive inhibition of the telomerase
Figure 4. Telomerase inhibitors and experimental angiogenesis inhibitors
A telomerase inhibitor used as a single agent will progressively reduce telomere length, but there is an expected time delay until cell death. Some angio-
genesis inhibitors will maintain a reduced tumor burden but will not eradicate the tumor or affect telomere length. Combinations of angiogenesis inhibitors
with telomerase inhibitors would be predicted to maintain a reduced tumor burden while producing progressively shortened telomeres, potentially leading
to preventing or delaying tumor recurrences.
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enzyme (Herbert et al., 1999) and that the agents will most like-
ly have to be administered to cancer patients for an extended
period. During this study (Herbert et al., 1999), there was no evi-
dence of any emergence of an alternative pathway for telomere
elongation. There have not been any studies on the long-term
effects of these template antagonists on normal somatic cells.
Inhibiting telomerase in precancerous cells: A novel cancer
prevention approach
Chemopreventive agents act by preventing the occurrence or
recurrence of cancer. Discovery of new chemopreventive
agents and assays to quantitatively analyze these agents is
therefore of vital importance.The effective use of chemopreven-
tive agents ultimately depends on the understanding of the
mechanism of action. A mechanism-based assay has been
developed using cultures of human breast-derived, epithelial
cells that spontaneously immortalize in cell culture (Herbert et
al., 2001). The endpoint, determining the frequency of cell
immortalization in the presence of chemopreventive agents,
has been validated using telomerase inhibitors (Herbert et al.,
2001). Cells were exposed to an oligonucleotide-based telomer-
ase antagonist using 2′ O-methyl-RNA targeting the human
telomerase RNA template region or infected with a retrovirus
expressing a dominant-negative mutant of the human telomer-
ase catalytic subunit. Both of these agents significantly reduced
the frequency of spontaneous immortalization of the breast
epithelial cells. In addition to preventing immortalization with
known telomerase inhibitors, other validated chemopreventive
agents were also shown to inhibit immortalization (Herbert et
al., 2001). The future identification of novel chemopreventive
agents that prevent the upregulation of telomerase may have
important clinical implications. These studies validate the appli-
cation of chemopreventive agents in a mechanism-based
assay, using cell immortalization as an endpoint. The results
also suggest that the telomerase ribonucleoprotein complex
may be an important target for breast cancer prevention.
Conclusions/future perspectives
Cancer remains a major cause of death in spite of substantial
progress in understanding its molecular mechanisms and the
development of an array of powerful treatments. The discovery
of validated targets and new drugs is therefore a high priority.
Telomerase-based drugs have the potential to act by novel
mechanisms that will provide new options for cancer therapy
and allow for unprecedented therapeutic specificity and efficacy.
Telomerase inhibitors, for example, might not only directly limit
or stop the growth of human tumors, but also might act in a syn-
ergistic fashion with existing therapeutic modalities and amplify
their effectiveness. After initial chemotherapy or surgery, telo-
merase inhibitors might be used to inhibit the recovery of resid-
ual cancer cells, making them more susceptible to attack by the
immune system or killing by existing chemotherapeutic agents
or other novel therapies as discussed in this review (Figures 3).
In addition, the combination of angiogenesis inhibitors with telo-
merase inhibitors could keep the tumor burden small as well as
lead to progressive telomere shortening (Figure 4).
In summary, we have described some of the major avenues
of targeting telomerase in human cancer cells. Immunotherapy
directed against telomerase-positive cells as well as strategies
using a suicide gene promoter targeted to hTERT-expressing
cells are currently under active investigation and in some
instances in early-stage clinical trials. These modalities have
the advantage of abolishing the lag phase that is required with
the classic mode of telomerase inhibition. However, these treat-
ments may also prove to be more toxic to normal somatic cells
expressing telomerase.The use of telomerase template antago-
nists would require a lag phase prior to any detrimental effects
on the cells and is unlikely to be a reasonable stand-alone strat-
egy in patients with a large tumor burden. Telomerase template
antagonists and other small molecule approaches to inhibit telo-
merase would be most effective in a situation of minimal resid-
ual disease or as an adjuvant treatment in combination with
conventional therapies (Figures 1 and 3). Telomerase inhibitors
will probably be used following standard therapies in which
there is no clinical evidence of disease in order to treat possible
micro metastases or in patients at high risk to develop cancer in
a chemoprevention approach. In these situations, which would
likely require prolonged treatment, it will be imperative that the
drugs have a low toxicity profile and be easily administered by
an oral or systemic “depo” route. At the present time, there is still
a large body of basic research to pursue, but it is encouraging
that formal preclinical investigation of telomerase inhibitors and
hTERTp-based oncolytic viruses has begun, and there are
already clinical studies underway with hTERT immunotherapy.
While the vast majority of studies are encouraging, the ultimate
utility of these and future drugs based on telomere biology will
only be determined after completion of clinical trials and use in
a broad range of cancer patients. However, it is reasonable to
anticipate that some surprises may arise as important lessons
from cell culture and animal models are validated in clinical trials.
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